RT Journal Article
T1 Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
A1 Shah, Neil P
A1 Garcia-Gutierrez, Valentin
A1 Jimenez-Velasco, Antonio
A1 Larson, Sarah
A1 Saussele, Susanne
A1 Rea, Delphine
A1 Mahon, François-Xavier
A1 Levy, Moshe Yair
A1 Gomez-Casares, Maria Teresa
A1 Pane, Fabrizio
A1 Nicolini, Franck-Emmanuel
A1 Mauro, Michael J
A1 Sy, Oumar
A1 Martin-Regueira, Patricia
A1 Lipton, Jeffrey H
K1 CML-CP
K1 Dasatinib
K1 Deep molecular response
K1 Imatinib
K1 Major molecular response
K1 Treatment-free remission
AB Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine kinase inhibitors to induce higher rates of sustained deep molecular response (DMR). DASFREE is an open-label, single-arm, multicenter phase II trial assessing TFR after dasatinib discontinuation in patients with CML-CP (N = 84). At 2 years, TFR was 46% in all patients. Multivariate analyses revealed statistically significant associations between 2-year TFR and duration of prior dasatinib (≥median; p = .0051), line of therapy (first line; p = .0138), and age (>65 years; p = .0012). No disease transformation occurred, and the most common adverse events experienced off treatment were musculoskeletal (observed in 30 patients); however, dasatinib withdrawal events were reported in nine patients (11%) by the investigator. Overall, these findings support the feasibility of discontinuing dasatinib for patients with CML-CP in sustained DMR in the first line and beyond.
PB Taylor & Francis
YR 2019
FD 2019-10-24
LK http://hdl.handle.net/10668/15255
UL http://hdl.handle.net/10668/15255
LA en
NO Shah, N. P., García-Gutiérrez, V., Jiménez-Velasco, A., Larson, S., Saussele, S., Rea, D., et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leukemia & Lymphoma/Leukemia And Lymphoma, 61(3), 650-659
DS RISalud
RD Apr 6, 2025